Delayed dilated cardiomyopathy for major burn injuries

Burns

Volumn 29, Issue 4, 2003, Pages 343-348

  Chen, Tzyy Jiin ^b   Shen, Bing Hwei ^a   Yeh, Fa Lai ^a   Lin, Jin Teh ^a   Ma, Hsu ^a   Huang, Chih Hung ^a   Fang, Rong Hwang ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Dilated cardiomyopathy; Major burn

Indexed keywords

AMIKACIN; ANTICOAGULANT AGENT; CEFOTAXIME; DIURETIC AGENT; GASOLINE; IMIPENEM; SULFAMETHOXAZOLE; TRIMETHOPRIM; VANCOMYCIN; VASODILATOR AGENT;

ADULT; ANAMNESIS; BODY SURFACE; BURN; CASE REPORT; CONFERENCE PAPER; FEMALE; FOLLOW UP; HEALTH STATUS; HEART DILATATION; HEART DISEASE; HUMAN; LABORATORY TEST; MEDICAL LITERATURE; OBSERVATION; PARAMETER; PHYSICAL EXAMINATION; RADIOGRAPHY; SURVIVAL RATE;

EID: 0038022614     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-4179(03)00007-X     Document Type: Conference Paper

References (58)

1. Munster A.M. Alterations of the host defense mechanism in burns. Surg. Clin. N Am. 50:1970;1217-1225.
2. Merriam T.W. Myocardial function following thermal injury. Circ. Res. 11:1962;669-673.
3. Fozzard H.A. Myocardial injury in burn shock. Ann. Surg. 154:1961;113-119.
4. Baxter C.R., Cook W.A., Shires G.T. Serum myocardial depressant factor of burn shock. Surg. Forum. 17:1966;1-2.
5. Fang R.W., Chen J.S., Lin J.T., King Y.H., Kuo J.S. A modified formula of GIK (glucose-insulin-potassium) therapy for treatment of extensive burn injury in dogs. J. Trauma. 29:1989;344-349.
6. Munster A.M., DiVincenti F.C., Foley F.D., Pruitt B.A. Cardiac infections in burns. J. Surg. 122:1971;524-527.
7. Pruitt B.A. Jr., Flemma R.J., DiVincenti F.C.et al. Pulmonary complications in burn patients. J. Thorac. Cardiovasc. Surg. 59:1970;7-20.
8. Mukherjee G.D., Basu P.G., Roy S., Seal M. Cardiomegaly following extensive burns. Ann. Plast. Surg. 19:1987;378-380.
9. Ross RS. Approach to the patient with congestive heart failure. In: McGehee HA, editors. Principles and practice of medicine. 18th ed. New Delhi: Amerind Publishing Co.; 1974. p. 206-20.
10. Hoshi V.V. Effects of burns on the heart - a clinicopathological study in children. JAMA. 211:1970;2130-2134.
11. Liedberg N.C., Reiss R., Artz C.P. Infection in burns. III. Septicemia, a common cause of death. Surg. Gynecol. Obstet. 99:1964;151-158.
12. Leffler J.N., Litvin Y., Barenholz Y., Lefer A.M. Proteolysis in formation of a myocardial depressant factor during shock. Am. J. Physiol. 224:1973;824-831.
13. Lefer A.M., Cowgill R., Marshall F.F.et al. Characterization of a myocardial depressant factor present in hemorrhagic shock. Am. J. Physiol. 213:1967;492-498.
14. Reilly J.M., Cunnion R.E., Burch-Whitman C., Parker M.M., Shelhamer J.H., Parrillo J.E. A circulating myocardial depressant substance is associated with cardiac dysfunction and peripheral hypoperfusion (lactic acedemia) in patients with septic shock. Chest. 95:1989;1072-1080.
15. Giroir B.P., Horton J.W., White D.J., McIntyre K.L., Lin C.Q. Inhibition of tumor necrosis factor (TNF) prevents myocardial dysfunction during burn shock. Am. J. Physiol. 267:1994;H118-24.
16. Herbertson M.J., Werner H.A., Goddard C.M.et al. Anti-tumor necrosis factor-alpha prevents decreased ventricular contractility in endotoxemic pigs. Am. J. Respir. Crit. Care Med. 152:1995;480-488.
17. Bryant D., Becker L., Richardson J.et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation. 97:1998;1375-1381.
18. Odeh M. Tumor necrosis factor-alpha as a myocardial depressant substance. Int. J. Cardiol. 42:1993;231-238.
19. Kapadia S., Lee J., Torre-amione G., Birdsall H.H., Ma T.S., Mann D.L. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J. Clin. Invest. 96:1995;1042-1052.
20. Torre-Amione G., Kapadia S., Lee J., Durand J.-B., Bies R.D., Young J.-B.et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 93:1996;704-711.
21. Kumar A., Haery C., Parrillo J.E. Myocardial dysfunction in septic shock. Crit. Care Clin. 16:2000;251-287.
22. Kumar A., Thota V., Dee L., Olson J., Uretz E., Parrillo J.E. Tumor necrosis factor-alpha and interleukin 1-beta are responsible for in vitro myocardial cell depression induced by juman septic shock serum. J. Exp. Med. 183:1996;949-958.
23. Waage A., Espevik T. Interleukin-1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice. J. Exp. Med. 167:1988;1987-1992.
24. Hegewisch S., Weh H.-J., Hossfeld D.K. TNF-induced cardiomyopathy. Lancet. 335:1990;294-295.
25. Habib F.M., Springall D.R., Davies G.J., Oakley C.M., Yacoub M.H., Polak J.M. Tumor necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet. 347:1996;1151-1155.
26. Horton J.W., White J. Role of xanthine oxidase and leukocytes in postburn cardiac dysfunction. J. Am. Coll. Surg. 181:1995;129-137.
27. Thomson P.D., Till G.O., Woolliscroft J.O. Superoxide dismutase prevents lipid peroxidation in burned patients. Burns. 16:1990;406-413.
28. Demling R.H., LaLonde C. Early postburn lipid peroxidation: effects of ibuprofen and allopurinol. Surgery. 107:1990;85-93.
29. Horton J.W., White J., Baxter C.R. The role of oxygen-derived free radicals in burn-induced myocardial contractile depression. J. Burn Care Rehabil. 9:1988;589-598.
30. Lefer A.M., Blattberg B. Comparison of the effects of two factors present in the plasma of shocked animals. J. Reticuloendothelial Soc. 5:1968;54-60.
31. Brand E.D., Suh T.K., Avery M.C. Reversal of postoligemic shock in the cat by hypervenobaric massive fluid therapy. Am. J. Physiol. 211:1966;1232-1240.
32. Johnson RA. Heart failure. In: Johnson RA, Haber E, Austen WG, editors. The practice of cardiology. Boston: Little Brown; 1980. p. 31-95.
33. Alexander J., Dainiak N., Berger H.J.et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N. Engl. J. Med. 300:1979;273-283.
34. Johnson R.A., Palacios I. Dilated cardiomyopathies of the adult (second of two parts). N. Engl. J. Med. 307:1982;1119-1126.
35. Abelmann WH. Clinical aspects of viral cardiomyopathy. In: Fowler NO, editor. Myocardial diseases. New York: Grune & Stratton; 1973. p. 253-79.
36. Lerner A.M., Wilson F.M., Reyes M.P. Enteroviruses and the heart. Mod. Concepts Cardiovasc. Dis. 44:1975;11-15.
37. Woodruff J.F. Viral myocarditis. Am. J. Pathol. 101:1980;427-479.
38. Ebeyesekere I., Hermon Y. Arbovirus heart disease: myocarditis and cardiomyopathy following dengue and chikungunya fever - a follow-up study. Am. Heart J. 85:1973;186-194.
39. Leak D., Meghji M. Toxoplasmic infection in cardiac disease. Am. J. Cardiol. 43:1979;841-849.
40. Rosenbaum M.B. Chagasic myocardiopathy. Prog. Cardiovasc. Dis. 7:1964;125-199.
41. Stein J.M., Pruitt B.A. Suppurative thrombophlebitis - a lethal iatrogenic disease. N. Engl. J. Med. 282:1970;1452-1455.
42. Beeson P.B., Brannon E.S., Warren J.V. Observations on the sites of removal of bacteria from the blood in patients with bacterial endocarditis. J. Exp. Med. 81:1945;9-23.
43. Weiss H., Ottenberg R. Relation between bacteria and temperature in subacute bacterial endocarditis. J. Infect. Dis. 50:1932;61-68.
44. Alexander J.W., Wixson D. Neutrophil dysfunction and sepsis in burn injury. Surg. Gynecol. Obstet. 130:1970;431-438.
45. Somerville W. Postcarditis myocardiopathy. Postgrad. Med. J. 48:1972;746-749.
46. Hesse D.G., Tracey K.J., Fong Y.et al. Cytokine appearance in human endotoxemia and primate bacteremia. Surg. Gynecol. Obstet. 166:1988;147-153.
47. Wakabayashi G., Gelfand J.A., Jung W.K.et al. Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli. J. Clin. Invest. 87:1991;1925-1935.
48. Giroir B.P., Johnson J.H., Brown T., Allen G.A., Beutler B. The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J. Clin. Invest. 90:1992;693-698.
49. Suffredini A.F., Frinnm R.E., Parker M.M.et al. The cardiovascular response of normal humans to the administration of endotoxin. N. Engl. J. Med. 321:1989;280-287.
50. Keshan disease research group of the Chinese academy of medical sciences, Beijing. Epidemiologic studies on the etiologic relationship of selenium and Keshan disease. Chin Med J (Engl) 1979;72:477-82.
51. Paplanus S.H., Zbar M.J., Hays J.W. Cardiac hypertrophy as a manifestation of chronic anemia. Am. J. Pathol. 34:1958;149-159.
52. Keye J.D. Death in potassium deficiency: report of a case including morphologic findings. Circulation. 5:1952;766-770.
53. Hall G.E., Cleghorn R.A. Cardiac lesions in adrenal insufficiency. Can. Med. Assoc. J. 39:1938;126-133.
54. Kumar A., Brar R., Wang P., Dee L., Skorupa G., Khadour F. Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. Am. J. Physiol. 276:1999;R265-76.
55. Robert A.J., Igor P. Dilated cardiomyopathies of the adult (first of two parts). N. Engl. J. Med. 307:1982;1051-1056.
56. Baandrup U., Florio R.A., Rehahn M., Richardson P.J., Olsen E.G.J. Critical analysis of endomyocardial biopsies from patients suspected of having cardiomyopathy. II. Comparison of histology and clinical/haemodynamic information. Br. Heart J. 45:1981;487-493.
57. Fuster V., Gersh B.J., Giuliani E.R., Tajik A.J., Brandenburg R.O., Frye R.L. The natural history of idiopathic dilated cardiomyopathy. Am. J. Cardiol. 47:1981;525-531.
58. Field B.J., Baxley W.A., Russell R.O., Hood W.P., Holt J.H. Left ventricular function and hypertrophy in cardiomyopathy with depressed ejection fraction. Circulation. 47:1973;1022-1031.